CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 3 (2022) Vis Cancer Med, 3 (2022) 2 Full HTML
Open Access
Review
Issue
Vis Cancer Med
Volume 3, 2022
Article Number 2
Number of page(s) 5
DOI https://doi.org/10.1051/vcm/2022002
Published online 06 April 2022

© The Authors, published by EDP Sciences, 2022

Licence Creative CommonsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Induced by type I and type III interferons (IFN), Mx proteins are important mediators of innate immunity against a broad spectrum of RNA and DNA viruses. The discovery of the first Mx protein, Mx1, dates back to 1962 when an inbred mouse strain showed resistance against lethal doses of influenza A virus (IVA) [1]. The resistance was caused by the gene MX1. Most of the other inbred strains of mice which carried nonfunctional MX1 alleles with large deletions or nonsense mutations were susceptible to FLUAV infection [2]. Human Mx proteins were discovered later via coincidence. A monoclonal antibody against mouse Mx1 exhibited cross-reaction against an interferon-induced protein in human cells. Two cytoplasmic Mx proteins, MxA and MxB, which are encoded by human MX1 and MX2 genes, respectively, were then identified [3]. Both genes are located on the distal part of the long arm of the human chromosome 21 [4]. Mx proteins are vertebrate-specific proteins found in zebrafish to humans.

Human MxA is a 78 kDa cytoplasmic protein closely associated with the smooth endoplasmic reticulum (ER) [5]. The importance of MxA as part of innate immunity has been underlined in extensive cell cultures and animal model studies. MxA was first discovered as an antiviral factor against negative-stranded RNA viruses, including the Orthomyxoviridae [6–8], Paramyxoviridae [9], Rhabdoviridae [6], and Bunyaviridae families [10, 11]. Further studies revealed that the antiviral activity of MxA stretches far beyond negative-stranded RNA viruses, including a striking diversity of positive-stranded RNA viruses [12], double-stranded RNA viruses [13], and some DNA viruses [14–17]. To avoid antibiotic abuse, clinical studies have shown that the combined interpretation of MxA with C-reactive protein (CRP) and/or procalcitonin dramatically improves the clinical sensitivity and specificity in discriminating between viral and bacterial infections (reviewed in [18]). However, the detailed molecular mechanisms underlying the antiviral activity of MxA remained elusive for a long time.

In addition to its antiviral activity, recent studies revealed the functions of MxA in different cancer types. An international multicenter study indicated that robust MxA expression is a positive indicator for breast cancer patients who might benefit from adjuvant chemotherapy [19]. In another retrospective study, a positive correlation between MxA and tumor-infiltrating lymphocytes (TIL) levels was revealed in triple-negative breast cancer (TNBC) cases [20]. Mushinski et al. demonstrated that stable exogenous MxA expression inhibited the motility and invasiveness of prostate carcinoma cells, both in vitro and in vivo [21]. Therefore, MxA may serve as a potential target for novel anti-cancer drug development.

Viral targets of MxA

Extensive efforts have been made among various viruses to identify the viral targets of MxA, as well as the molecular mechanism of MxA-mediated autoimmunity against virus infections.

The influenza virus belongs to the family of Orthomyxoviridae, which is the most well-studied myxovirus family. Accumulating evidence has demonstrated that the nucleoprotein (NP) component of Orthomyxoviruses is the main determinant of MxA susceptibility. Sequestration of NP by MxA in the cytoplasm leads to the block of viral amplification and infection [22].

As the key effector protein against IVAs, MxA has been shown to block viral replication at an early stage of the infection [7]. Upon IVA infection, viral mRNA synthesis in MxA-positive cells was reported to be within a normal level, while viral protein synthesis and genome amplification was strongly inhibited, suggesting that MxA interferes with either viral protein translation in the cytoplasm or translocation of newly synthesized viral proteins to the cell nucleus [7]. Growing evidence suggests that MxA confers protection against IVA by targeting the viral NP protein [23–26]. The genome of the IVA is segmented into eight RNA molecules, each compacted as a rod-shaped ribonucleoprotein complex (RNP) with the NP proteins. The RNP structure is crucial for the viral infection cycle. Upon infection, RNPs are delivered to the cytoplasm of host cells through endocytosis, followed by active transportation into the nucleus. After transcription of the vRNAs in the nucleus, mRNAs are exported to the cytoplasm for translation of the viral proteins NP, PB1, PB2, and PA. Newly synthesized NP is then imported back into the nucleus for the production of nascent virions (reviewed in [27]). Therefore, sequestration of the viral RNP in the cytoplasm by MxA upon infection can impair the IVA replication process at an early stage, providing protection against further infection.

There are several lines of evidence supporting the importance of MxA-NP interaction against IVA infection. Utilizing a transient influenza virus transcription reporter assay system, Turan et al. revealed that the nuclear-localized MxA strongly inhibits the influenza virus transcription, which may be neutralized by over-expression of NP, but not (or only slightly) by other RNA polymerase subunits PB1, PB2, and PA [24]. Furthermore, studies using influenza virus-infected cells proved that apart from the nuclear-localized MxA, cytosolic MxA also interacts with NP in vitro, which may confer resistance upon infection of the influenza virus.

Besides blocking the infection of human viruses, human MxA also acts as an efficient protective barrier against the zoonotic introduction of pathogenic viruses into the human population. However, some viruses have successfully evaded MxA restriction through evolution, such as the IVA H1N1 strain, which caused the 2009 pandemic, and a thogotovirus isolate, another member of the Orthomyxoviridae [28]. Individual substitution of each H1N1 component involved in vRNA replication with the H5N1 counterpart in a polymerase reconstitution assay proved that NP was the main determinant of MxA sensitivity [25]. An analysis of the adaptive mutations in the NPs of two MxA resistant IVA strains revealed that the resistance-related mutations were clustered in a surface-exposed region in the body domain of NP. The introduction of this cluster into the MxA-sensitive strain resulted in a gain of resistance, although viral replication fitness was affected [26]. Similarly, two amino acid substitutions (G327R and R328V) in the viral nucleoprotein of the MxA-resistant thogotovirus isolate were shown to be responsible for its resistance. Unlike in the cases of IVAs [26], when the R328V mutation was introduced into the MxA-sensitive thogotovirus isolate SiAr126, the resulting recombinant virus gained complete MxA resistance without any viral fitness loss, indicating even greater zoonotic potential than previously expected. These studies demonstrate that NP is the essential viral component underlying MxA susceptibility and that NP alone is sufficient to determine MxA susceptibility in Orthomyxoviruses. Experimental evidence with the La Crosse Virus (LACV), which belongs to the Bunyaviridae family, demonstrated a direct interaction between MxA and the virus nucleocapsid (N) protein, suggesting a similar working mode of MxA with the Orthomyxoviruse NP. Replication of LACV takes place in the cytoplasm of infected cells through the budding of nucleocapsids into the Golgi apparatus. Electron microscopy (EM) studies have shown that MxA binds to the viral N protein and forms cytoplasmic complexes which accumulate in the perinuclear area, forming highly ordered fibrillary structures [29]. Further studies have revealed that MxA and the viral N protein both localize to a specific sub-compartment of the smooth ER, resulting in efficient sequestration of N, which leads to the depletion of this important viral component from viral replication sites, thereby preventing the assembly of new virus particles [30]. Interestingly, tubular structures of MxA entangled with a viral structural protein were also observed in another study with the West Nile virus (WNV), which belongs to the Flaviviridae family. While MxA was reported to be less important in restricting HCV and WNVkun replication [31, 32], one study has shown that in an expression-replication system, in which MxA is retargeted from cytoplasmic inclusions to the ER during WNVkun replication, the MxA protein can sequester the capsid (C) protein of WNV in tubular structures in the cytoplasm and reduce the titers of secreted viral particles [33]. Using a rapid and compartmentalized replication and assembly strategy, WNV can hinder the recognition of the capsid protein by MxA in vivo, resulting in evasion from MxA-mediated host surveillance. More importantly, this evasion can actually be reversed by the expression of recombinant ER-targeting MxA, which is translocated to intracellular viral assembly sites upon infection.

Although the formation of tubular bundles indicates an interaction between MxA and the C protein of the WNVkun, there is no direct evidence showing the physical interaction between these two proteins, probably due to lack of other cellular factors [33]. In hepatitis B virus (HBV) infected cells, physical interaction between MxA and the HBV core antigen protein (HBcAg) has been elucidated, which results in the immobilization of HBcAg in the cytoplasm and hampers viral capsid formation [15]. Interestingly, MxA seems to restrict the positive-sense RNA virus Semliki Forest virus (SFV) by targeting a component of the replicase but not the structural protein [12].

In summary, MxA targets highly divergent proteins in different types of viruses. And the molecular mechanisms for MxA to recognize distinct viral proteins, which evolve rapidly to evade recognition by the host immune system, are of vital importance for containing the epidemic caused by these viruses.

Crystal structure and the ring-like model of MxA depicting its antiviral mechanism

The MxA protein belongs to the dynamin superfamily of multi-domain GTPases, which are characterized by the self-assembly ability and assembly-stimulated GTPase activity. Like dynamin, MxA can form highly-ordered oligomers and self-assemble into ring-like or helical structures in vitro [34]. Both MxA and dynamin can tubulate liposomes [35], but stimulated GTPase activity upon this liposome-induced assembly is observed only for dynamin, not MxA [36], suggesting different cellular functions of these two mechano-chemical GTPases upon activation. GTP binding allows for the dimerization of MxA via the GTPase (G) domain and facilitates ER membrane-associated assembly of MxA, whereas GTP hydrolysis promotes the redistribution of MxA from cellular membranes to viral targets [37].

In order to elucidate the molecular mechanisms of MxA action as a broadly-acting antiviral effector, high-resolution crystal structures of the MxA stalk region and the full-length MxA protein were determined successively. Together with the results of biochemical studies and EM studies, a more detailed picture of MxA’s antiviral function has now been elucidated.

Back in 2010, we solved the crystal structure of the stalk region of MxA (PDB: 3LJB) [38], followed by the near-full-length MxA crystal structure in 2011 (PDB: 3SZR) [39]. MxA is an elongated molecule composed of three domains, an N-terminal GTPase domain, a bundle-signaling-element (BSE), and a C-terminal stalk responsible for self-assembly (Figure 1). The unstructured L4 loop has been proposed as the lipid-binding moiety of MxA based on biochemical analysis [36]. The most variable region of Mx proteins is L4, which accounts for the antiviral specificity probably by direct interaction with different target viral proteins [40]. Biochemical studies using single-molecule fluorescence resonance energy transfer (smFRET) revealed that while the G domain-BSE region prefers to adopt an “open” state in nucleotide-free conditions, loading of GTP changed the conformational preference to the “closed” state. The frequent relative movement was also observed between the BSE and the stalk via hinge 1, which may be key elements for mechano-chemical coupling of MxA molecules [41]. Unlike the linear MxA filaments in our crystal structure, MxA oligomerizes into ring-like structures around tubulated liposomes were observed in EM studies [36]. As the experimental data supporting the role of MxA-NP interaction during MxA-mediated influenza virus restriction was accumulating, a theory was put forward that the oligomeric rings represent antiviral molecular machines that oligomerize around the tubular structure of viral ribonucleocapsids (RNPs) [39].

thumbnail Figure 1

Structure of the MxA monomer. Ribbon-type representation of an MxA monomer. The G domain, BSE, and stalk domain are colored ruby, light blue and pale yellow, respectively.

Based on the evidence from previous EM studies, this theory was subsequently depicted by a ring-like MxA oligomer model, which was constructed using the structure of near-full-length MxA as the building block (Figure 2) [39, 42]. This MxA-ring has a diameter of 24 nm, and a 23° rotation around the hydrophobic interface-1 was introduced between the building block dimers to facilitate the formation of the ring. The inner layer of the MxA-ring is composed of the stalk domains and the outer layer of the G domains, allowing for transient dimerization with the G domains from adjacent rings (Video 1). The predicted substrate-binding loop L4 points towards the center of the ring and allowed for interactions with viral components, like nucleocapsids. The architecture of this MxA-ring model was later substantiated by a subsequent cryo-EM analysis on MxA-decorated lipid tubules [36, 43]. Upon GTP binding, the G domains from neighboring rings come into contact and confer stimulated GTP hydrolysis. These actions trigger conformational changes of MxA molecules, which collectively produce a synchronized power stroke, resulting in the sequestration and disintegration of enwrapped essential viral components and eventually the disruption of viral replication [39, 44].

thumbnail Figure 2

Model of Ring-like MxA Oligomer. A. Structural model of the MxA tetramer. The indicated 23° rotation around the hydrophobic interface-1 leads to the formation of the ring-like MxA oligomer model. B. A model of the ring-like MxA oligomer. The MxA-ring is composed of 16 constitutive dimers, each represented by a distinct color.
Video 1

To better present the 3D structure of the ring-like MxA oligomer, this movie was made using PyMOL. The first and second appearing MxA monomers are colored cyan and green, respectively. The other 15 dimers are differently colored and gradually emerge to form the ring-like structure.

Remarkably, MxA and the WNV C protein form tightly packed bundles built from hollow tubes with a diameter of ~30 nm [33]. A similar ultrastructure was also reported for the complex of MxA LACV NP [29]. In both cases, the viral-component sequestration manner of MxA resembles what was found for the influenza virus. The flexibility of interface-1, to a certain extent, provides freedom of rotation between the building block MxA dimers, which facilitates the formation of MxA-rings with proper diameters to contain target viral structures with various sizes, thereby explaining the broad antiviral spectrum of MxA (reviewed in [45]).

Future prospects

Substantial efforts and achievements have been made by researchers over the past few decades in studying the highly diverse viral targets of MxA, as well as the evolutionary strategies of viruses in evading MxA-mediated host surveillance. Further studies, especially the high-resolution interpretation of MxA-viral component complexes, are required to elucidate this issue, which will contribute to the development of novel and timely antiviral means against corresponding infectious diseases.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgments

We would like to thank Mr. Christopher Lavender for his kind revision of the English language.

References

  1. Lindenmann J. Resistance of mice to mouse-adapted influenza A virus. Virology. 1962;16:203–204. [Google Scholar]
  2. Staeheli P, Grob R, Meier E, et al. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Molecular and Cellular Biology. 1988;8(10):4518–4523. [PubMed] [Google Scholar]
  3. Aebi M, Fah J, Hurt N, et al. cDNA structures and regulation of two interferon-induced human Mx proteins. Molecular and Cellular Biology. 1989;9(11):5062–5072. [PubMed] [Google Scholar]
  4. Horisberger MA, Wathelet M, Szpirer J, et al. cDNA cloning and assignment to chromosome 21 of IFI-78K gene, the human equivalent of murine Mx gene. Somatic Cell and Molecular Genetics. 1988;14(2):123–131. [Google Scholar]
  5. Stertz S, Reichelt M, Krijnse-Locker J, et al. Interferon-induced, antiviral human MxA protein localizes to a distinct subcompartment of the smooth endoplasmic reticulum. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research. 2006;26(9):650–660. [CrossRef] [PubMed] [Google Scholar]
  6. Pavlovic J, Zurcher T, Haller O, et al. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. Journal of Virology. 1990;64(7):3370–3375. [CrossRef] [PubMed] [Google Scholar]
  7. Pavlovic J, Haller O, Staeheli P. Human and mouse Mx proteins inhibit different steps of the influenza virus multiplication cycle. Journal of Virology. 1992;66(4):2564–2569. [CrossRef] [PubMed] [Google Scholar]
  8. Frese M, Kochs G, Meier-Dieter U, et al. Human MxA protein inhibits tick-borne Thogoto virus but not Dhori virus. Journal of Virology. 1995;69(6):3904–3909. [CrossRef] [PubMed] [Google Scholar]
  9. Schnorr JJ, Schneider-Schaulies S, Simon-Jodicke A, et al. MxA-dependent inhibition of measles virus glycoprotein synthesis in a stably transfected human monocytic cell line. Journal of Virology. 1993;67(8):4760–4768. [CrossRef] [PubMed] [Google Scholar]
  10. Frese M, Kochs G, Feldmann H, et al. Inhibition of bunyaviruses, phleboviruses, and hantaviruses by human MxA protein. Journal of Virology. 1996;70(2):915–923. [CrossRef] [PubMed] [Google Scholar]
  11. Hefti HP, Frese M, Landis H, et al. Human MxA protein protects mice lacking a functional alpha/beta interferon system against La crosse virus and other lethal viral infections. Journal of Virology. 1999;73(8):6984–6991. [CrossRef] [PubMed] [Google Scholar]
  12. Landis H, Simon-Jodicke A, Kloti A, et al. Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins. Journal of Virology. 1998;72(2):1516–1522. [CrossRef] [PubMed] [Google Scholar]
  13. Mundt E. Human MxA protein confers resistance to double-stranded RNA viruses of two virus families. The Journal of General Virology. 2007;88(Pt 4):1319–1323. [Google Scholar]
  14. Netherton CL, Simpson J, Haller O, et al. Inhibition of a large double-stranded DNA virus by MxA protein. Journal of Virology. 2009;83(5):2310–2320. [CrossRef] [PubMed] [Google Scholar]
  15. Li N, Zhang L, Chen L, et al. MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen. Hepatology. 2012;56(3):803–811. [CrossRef] [PubMed] [Google Scholar]
  16. Gordien E, Rosmorduc O, Peltekian C, et al. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. Journal of Virology. 2001;75(6):2684–2691. [CrossRef] [PubMed] [Google Scholar]
  17. Mitchell PS, Emerman M, Malik HS. An evolutionary perspective on the broad antiviral specificity of MxA. Current Opinion in Microbiology. 2013;16(4):493–499. [CrossRef] [PubMed] [Google Scholar]
  18. Zav’yalov VP, Hamalainen-Laanaya H, Korpela TK, et al. Interferon-inducible myxovirus resistance proteins: potential biomarkers for differentiating viral from bacterial infections. Clinical Chemistry. 2019;65(6):739–750. [CrossRef] [PubMed] [Google Scholar]
  19. Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine. 2014;20(11):1301–1309. [Google Scholar]
  20. Kim YA, Lee HJ, Heo SH, et al. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. Breast Cancer Research and Treatment. 2016;156(3):597–606. [CrossRef] [PubMed] [Google Scholar]
  21. Mushinski JF, Nguyen P, Stevens LM, et al. Inhibition of tumor cell motility by the interferon-inducible GTPase MxA. The Journal of Biological Chemistry. 2009;284(22):15206–15214. [Google Scholar]
  22. Kochs G, Haller O. GTP-bound human MxA protein interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae). The Journal of Biological Chemistry. 1999;274(7):4370–4376. [Google Scholar]
  23. Deeg CM, Hassan E, Mutz P, et al. In vivo evasion of MxA by avian influenza viruses requires human signature in the viral nucleoprotein. The Journal of Experimental Medicine. 2017;214(5):1239–1248. [Google Scholar]
  24. Turan K, Mibayashi M, Sugiyama K, et al. Nuclear MxA proteins form a complex with influenza virus NP and inhibit the transcription of the engineered influenza virus genome. Nucleic Acids Research. 2004;32(2):643–652. [Google Scholar]
  25. Zimmermann P, Manz B, Haller O, et al. The viral nucleoprotein determines Mx sensitivity of influenza A viruses. Journal of Virology. 2011;85(16):8133–8140. [CrossRef] [PubMed] [Google Scholar]
  26. Manz B, Dornfeld D, Gotz V, et al. Pandemic influenza A viruses escape from restriction by human MxA through adaptive mutations in the nucleoprotein. PLoS Pathogens. 2013;9(3):e1003279. [Google Scholar]
  27. Zheng W, Tao YJ. Structure and assembly of the influenza A virus ribonucleoprotein complex. FEBS Letters. 2013;587(8):1206–1214. [CrossRef] [PubMed] [Google Scholar]
  28. Fuchs J, Oschwald A, Graf L, et al. Tick-transmitted thogotovirus gains high virulence by a single MxA escape mutation in the viral nucleoprotein. PLoS Pathogens. 2020;16(11):e1009038. [Google Scholar]
  29. Kochs G, Janzen C, Hohenberg H, et al. Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(5):3153–3158. [Google Scholar]
  30. Reichelt M, Stertz S, Krijnse-Locker J, et al. Missorting of LaCrosse virus nucleocapsid protein by the interferon-induced MxA GTPase involves smooth ER membranes. Traffic. 2004;5(10):772–784. [Google Scholar]
  31. Frese M, Pietschmann T, Moradpour D, et al. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. The Journal of General Virology. 2001;82(Pt 4):723–733. [Google Scholar]
  32. Hoenen A, Liu W, Kochs G, et al. West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein. The Journal of General Virology. 2007;88(Pt 11):3013–3017. [Google Scholar]
  33. Hoenen A, Gillespie L, Morgan G, et al. The West Nile virus assembly process evades the conserved antiviral mechanism of the interferon-induced MxA protein. Virology. 2014;448:104–116. [Google Scholar]
  34. Kochs G, Haener M, Aebi U, et al. Self-assembly of human MxA GTPase into highly ordered dynamin-like oligomers. The Journal of Biological Chemistry. 2002;277(16):14172–14176. [Google Scholar]
  35. Accola MA, Huang B, Al Masri A, et al. The antiviral dynamin family member, MxA, tubulates lipids and localizes to the smooth endoplasmic reticulum. The Journal of biological chemistry. 2002;277(24):21829–21835. [Google Scholar]
  36. von der Malsburg A, Abutbul-Ionita I, Haller O, et al. Stalk domain of the dynamin-like MxA GTPase protein mediates membrane binding and liposome tubulation via the unstructured L4 loop. The Journal of Biological Chemistry. 2011;286(43):37858–37865. [Google Scholar]
  37. Dick A, Graf L, Olal D, et al. Role of nucleotide binding and GTPase domain dimerization in dynamin-like myxovirus resistance protein A for GTPase activation and antiviral activity. The Journal of Biological Chemistry. 2015;290(20):12779–12792. [Google Scholar]
  38. Gao S, von der Malsburg A, Paeschke S, et al. Structural basis of oligomerization in the stalk region of dynamin-like MxA. Nature. 2010;465(7297):502–506. [Google Scholar]
  39. Gao S, von der Malsburg A, Dick A, et al. Structure of myxovirus resistance protein a reveals intra- and intermolecular domain interactions required for the antiviral function. Immunity. 2011;35(4):514–525. [CrossRef] [PubMed] [Google Scholar]
  40. Patzina C, Haller O, Kochs G Structural requirements for the antiviral activity of the human MxA protein against Thogoto and influenza A virus. The Journal of Biological Chemistry. 2014;289(9):6020–6027. [Google Scholar]
  41. Chen Y, Zhang L, Graf L, et al. Conformational dynamics of dynamin-like MxA revealed by single-molecule FRET. Nature Communications. 2017;8:15744. [Google Scholar]
  42. Daumke O, Gao S, von der Malsburg A, et al. Structure of the MxA stalk elucidates the assembly of ring-like units of an antiviral module. Small GTPases. 2010;1(1):62–64. [Google Scholar]
  43. Alvarez FJD, He S, Perilla JR, et al. CryoEM structure of MxB reveals a novel oligomerization interface critical for HIV restriction. Science Advances. 2017;3(9):e1701264. [Google Scholar]
  44. Rennie ML, McKelvie SA, Bulloch EM, et al. Transient dimerization of human MxA promotes GTP hydrolysis, resulting in a mechanical power stroke. Structure. 2014;22(10):1433–1445. [Google Scholar]
  45. Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research. 2011;31(1):79–87. [CrossRef] [PubMed] [Google Scholar]

Cite this article as: Cite this article as: Liao S & Gao S. MxA: a broadly acting effector of interferon-induced human innate immunity. Visualized Cancer Medicine. 2022. 3, 2.

All Figures

thumbnail Figure 1

Structure of the MxA monomer. Ribbon-type representation of an MxA monomer. The G domain, BSE, and stalk domain are colored ruby, light blue and pale yellow, respectively.
In the text
thumbnail Figure 2

Model of Ring-like MxA Oligomer. A. Structural model of the MxA tetramer. The indicated 23° rotation around the hydrophobic interface-1 leads to the formation of the ring-like MxA oligomer model. B. A model of the ring-like MxA oligomer. The MxA-ring is composed of 16 constitutive dimers, each represented by a distinct color.
In the text

All Movies

Video 1

To better present the 3D structure of the ring-like MxA oligomer, this movie was made using PyMOL. The first and second appearing MxA monomers are colored cyan and green, respectively. The other 15 dimers are differently colored and gradually emerge to form the ring-like structure.

In the text

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.